fb-pixel Skip to main content

Latest Headlines in Biotech

Vertex Pharmaceuticals signage is displayed at the entrance to the company's building in Boston/

Vertex tumbles after halting development of liver-disease drug

Vertex ended a closely watched effort to develop a therapy for liver disease, a setback in the biotech’s quest to broaden its offerings beyond cystic fibrosis drugs. The shares fell as much 15 percent after US markets closed Thursday.

Moderna’s production and lab facility in Norwood.

Moderna files for clearance of COVID-19 vaccine in adolescents

Authorization by the Food and Drug Administration would make it the second vaccine cleared for this age group in the US.

The approval of Biogen’s new Alzheimer’s disease treatment spurred broad gains in the sector, driving the Nasdaq Biotech Index up to its highest level in more than a month.

Biotech shares soar as Biogen drug approval stokes optimism

Traders viewed the approval as a precedent-setting event which could signal the Food and Drug Administration’s stance on other new medicines, not just those tied to the brain-wasting disease

Blackstone recently put local executive Nick Galakatos, who runs Blackstone Life Sciences out of Cambridge, on BioMed’s board of directors.

How a New York private equity giant became Boston’s biggest commercial landlord and biotech investor

Blackstone has invested billions in the Boston-area economy in recent years, through real estate and life sciences deals. This huge bet underscores how Boston and Cambridge represent the industry’s most important global hub.

The CEO of Invaio Sciences, Ignacio Martinez.

Agricultural biotech Invaio raises $89 million to improve crop health

The Cambridge startup, launched out of Flagship Pioneering, hopes to develop targeted approaches to warding off insects and preventing diseases in vegetables and other plants.

Biogen's headquarters in Cambridge.

Biogen taps Ginkgo Bioworks to work on gene therapy manufacturing program

The companies’ goal is to make the production process more efficient.

Jason Kelly, cofounder and chief executive of Ginkgo Bioworks.

Ginkgo unveils its stock ticker, a biotech venture fund raises $515m, and a unicorn is born

Here’s a roundup of local life-science deals and fundraising events that people are talking about this week.

Dr. Dan Barouch, head of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, is the senior author of the new study.

Pfizer and Moderna vaccines produce robust immune responses in pregnant and nursing women

The results of the Beth Israel study are similar to those in another study published in March in the American Journal of Obstetrics and Gynecology by researchers from Massachusetts General Hospital and Brigham and Women’s Hospital.